+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

T-Cell Immunotherapy Market Research Report by Type of Therapy, by Product Class, by Indication, by Region - Global Forecast to 2025 - Cumulative Impact of COVID-19

  • ID: 4986070
  • Report
  • September 2021
  • Region: Global
  • 199 pages
  • 360iResearch™
UP TO OFF
until Sep 30th 2021
The Global T-Cell Immunotherapy Market Will Grow to USD 7,602.60 Million by 2025, at a CAGR of 12.69%

FEATURED COMPANIES

  • Apac Biotech
  • CARsgen Therapeutics, Ltd
  • Eureka Therapeutics, Inc.
  • JW CreaGene Co., Ltd.
  • Neogene Therapeutics
  • Oxford Vacmedix
The Global T-Cell Immunotherapy Market size was estimated at USD 4,182.75 Million in 2020 and expected to reach USD 4,712.10 Million in 2021, at a Compound Annual Growth Rate (CAGR) 12.69% to reach USD 7,602.60 Million by 2025.



Market Statistics:


The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2025 are considered the forecast period.

Market Segmentation & Coverage:


This research report categorizes the T-Cell Immunotherapy to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Type of Therapy, the T-Cell Immunotherapy Market was studied across CAR-T, TCR, and TIL.
  • Based on Mechanism Of Action, the T-Cell Immunotherapy Market was studied across Active Immunotherapy and Passive Immunotherapy.
  • Based on Product Class, the T-Cell Immunotherapy Market was studied across Bispecific Antibodies, Cytokines, Monoclonal Antibodies, and Oncolytic Virus Therapy.
  • Based on Indication, the T-Cell Immunotherapy Market was studied across B-cell Malignancies, Liver Cancer, Prostate Cancer, and Renal Cell Carcinoma.
  • Based on Region, the T-Cell Immunotherapy Market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:


The FPNV Positioning Matrix evaluates and categorizes the vendors in the T-Cell Immunotherapy Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:


The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global T-Cell Immunotherapy Market, including Adaptimmune Therapeutics PLC, Apac Biotech, Atara Biotherapeutics, Inc., Autolus Limited, bluebird bio, Inc., Bristol-Myers Squibb Company, CARsgen Therapeutics, Ltd, Cellectis SA, Chimera Bioengineering, Dendreon Pharmaceuticals LLC, Eureka Therapeutics, Inc., Gilead Sciences, Inc., Green Cross Corporation, Innovative Cellular Therapeutics, Iovance Biotherapeutics, Inc., JW CreaGene Co., Ltd., LAVA Therapeutics BV, Lyell Immunopharma, Neogene Therapeutics, NeoTX Therapeutics, Novartis AG, Oxford Vacmedix, Poseida Therapeutics, TScan Therapeutics, Inc., Xenetic Biosciences, and ZIOPHARM Oncology.

The report provides insights on the following pointers:


1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:


1. What is the market size and forecast of the Global T-Cell Immunotherapy Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global T-Cell Immunotherapy Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global T-Cell Immunotherapy Market?
4. What is the competitive strategic window for opportunities in the Global T-Cell Immunotherapy Market?
5. What are the technology trends and regulatory frameworks in the Global T-Cell Immunotherapy Market?
6. What is the market share of the leading vendors in the Global T-Cell Immunotherapy Market?
7. What modes and strategic moves are considered suitable for entering the Global T-Cell Immunotherapy Market?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Apac Biotech
  • CARsgen Therapeutics, Ltd
  • Eureka Therapeutics, Inc.
  • JW CreaGene Co., Ltd.
  • Neogene Therapeutics
  • Oxford Vacmedix
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
3.1. Introduction
3.2. Market Outlook
3.3. Type of Therapy Outlook
3.4. Mechanism Of Action Outlook
3.5. Product Class Outlook
3.6. Indication Outlook
3.7. Region Outlook
3.8. Competitor Outlook

4. Market Overview
4.1. Introduction
4.2. Cumulative Impact of COVID-19

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing Prevalence of Cancer and Autoimmune Diseases
5.1.1.2. Use of Cell-Based Targeted Therapies
5.1.1.3. Increasing R&D Supporting T-cell Immunotherapy
5.1.2. Restraints
5.1.2.1. High Cost of Treatment
5.1.3. Opportunities
5.1.3.1. Commercialisation and Funding by Pharmaceutical Companies
5.1.3.2. Attractiveness of Off-the-Shelf Therapies
5.1.4. Challenges
5.1.4.1. Neurologic Toxicities and Cytokine Release Syndrome
5.2. Porters Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Threat of Substitutes
5.2.3. Bargaining Power of Customers
5.2.4. Bargaining Power of Suppliers
5.2.5. Industry Rivalry

6. T-Cell Immunotherapy Market, by Type of Therapy
6.1. Introduction
6.2. CAR-T
6.3. TCR
6.4. TIL

7. T-Cell Immunotherapy Market, by Mechanism Of Action
7.1. Introduction
7.2. Active Immunotherapy
7.3. Passive Immunotherapy

8. T-Cell Immunotherapy Market, by Product Class
8.1. Introduction
8.2. Bispecific Antibodies
8.3. Cytokines
8.4. Monoclonal Antibodies
8.5. Oncolytic Virus Therapy

9. T-Cell Immunotherapy Market, by Indication
9.1. Introduction
9.2. B-cell Malignancies
9.3. Liver Cancer
9.4. Prostate Cancer
9.5. Renal Cell Carcinoma

10. Americas T-Cell Immunotherapy Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific T-Cell Immunotherapy Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Thailand

12. Europe, Middle East & Africa T-Cell Immunotherapy Market
12.1. Introduction
12.2. France
12.3. Germany
12.4. Italy
12.5. Netherlands
12.6. Qatar
12.7. Russia
12.8. Saudi Arabia
12.9. South Africa
12.10. Spain
12.11. United Arab Emirates
12.12. United Kingdom

13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion

14. Company Usability Profiles
14.1. Adaptimmune Therapeutics PLC
14.2. Apac Biotech
14.3. Atara Biotherapeutics, Inc.
14.4. Autolus Limited
14.5. bluebird bio, Inc.
14.6. Bristol-Myers Squibb Company
14.7. CARsgen Therapeutics, Ltd
14.8. Cellectis SA
14.9. Chimera Bioengineering
14.10. Dendreon Pharmaceuticals LLC
14.11. Eureka Therapeutics, Inc.
14.12. Gilead Sciences, Inc.
14.13. Green Cross Corporation
14.14. Innovative Cellular Therapeutics
14.15. Iovance Biotherapeutics, Inc.
14.16. JW CreaGene Co., Ltd.
14.17. LAVA Therapeutics BV
14.18. Lyell Immunopharma
14.19. Neogene Therapeutics
14.20. NeoTX Therapeutics
14.21. Novartis AG
14.22. Oxford Vacmedix
14.23. Poseida Therapeutics
14.24. TScan Therapeutics, Inc.
14.25. Xenetic Biosciences
14.26. ZIOPHARM Oncology

15. Appendix
15.1. Discussion Guide
15.2. License & Pricing

List of Figures
FIGURE 1. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, 2020 VS 2025 (USD MILLION)
FIGURE 2. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2020 (USD MILLION)
FIGURE 3. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2020 (USD MILLION)
FIGURE 4. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2020 (USD MILLION)
FIGURE 5. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2020 (USD MILLION)
FIGURE 6. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2020 (USD MILLION)
FIGURE 7. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2025 (USD MILLION)
FIGURE 8. GLOBAL T-CELL IMMUNOTHERAPY MARKET: MARKET DYNAMICS
FIGURE 9. GLOBAL T-CELL IMMUNOTHERAPY MARKET: PORTERS FIVE FORCES ANALYSIS
FIGURE 10. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2020 VS 2025 (%)
FIGURE 11. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2020 VS 2025 (USD MILLION)
FIGURE 12. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2025
FIGURE 13. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY CAR-T, 2018-2025 (USD MILLION)
FIGURE 14. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY CAR-T, BY REGION, 2020 VS 2025 (USD MILLION)
FIGURE 15. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY TCR, 2018-2025 (USD MILLION)
FIGURE 16. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY TCR, BY REGION, 2020 VS 2025 (USD MILLION)
FIGURE 17. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY TIL, 2018-2025 (USD MILLION)
FIGURE 18. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY TIL, BY REGION, 2020 VS 2025 (USD MILLION)
FIGURE 19. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2020 VS 2025 (%)
FIGURE 20. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2020 VS 2025 (USD MILLION)
FIGURE 21. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2025
FIGURE 22. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2018-2025 (USD MILLION)
FIGURE 23. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, BY REGION, 2020 VS 2025 (USD MILLION)
FIGURE 24. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2018-2025 (USD MILLION)
FIGURE 25. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, BY REGION, 2020 VS 2025 (USD MILLION)
FIGURE 26. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2020 VS 2025 (%)
FIGURE 27. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2020 VS 2025 (USD MILLION)
FIGURE 28. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2025
FIGURE 29. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2018-2025 (USD MILLION)
FIGURE 30. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY BISPECIFIC ANTIBODIES, BY REGION, 2020 VS 2025 (USD MILLION)
FIGURE 31. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY CYTOKINES, 2018-2025 (USD MILLION)
FIGURE 32. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY CYTOKINES, BY REGION, 2020 VS 2025 (USD MILLION)
FIGURE 33. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2025 (USD MILLION)
FIGURE 34. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2020 VS 2025 (USD MILLION)
FIGURE 35. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2025 (USD MILLION)
FIGURE 36. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2020 VS 2025 (USD MILLION)
FIGURE 37. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2020 VS 2025 (%)
FIGURE 38. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2020 VS 2025 (USD MILLION)
FIGURE 39. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025
FIGURE 40. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY B-CELL MALIGNANCIES, 2018-2025 (USD MILLION)
FIGURE 41. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY B-CELL MALIGNANCIES, BY REGION, 2020 VS 2025 (USD MILLION)
FIGURE 42. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY LIVER CANCER, 2018-2025 (USD MILLION)
FIGURE 43. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY LIVER CANCER, BY REGION, 2020 VS 2025 (USD MILLION)
FIGURE 44. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY PROSTATE CANCER, 2018-2025 (USD MILLION)
FIGURE 45. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2020 VS 2025 (USD MILLION)
FIGURE 46. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2025 (USD MILLION)
FIGURE 47. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2020 VS 2025 (USD MILLION)
FIGURE 48. AMERICAS T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2025 (USD MILLION)
FIGURE 49. ARGENTINA T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2025 (USD MILLION)
FIGURE 50. BRAZIL T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2025 (USD MILLION)
FIGURE 51. CANADA T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2025 (USD MILLION)
FIGURE 52. MEXICO T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2025 (USD MILLION)
FIGURE 53. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2025 (USD MILLION)
FIGURE 54. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2025 (USD MILLION)
FIGURE 55. AUSTRALIA T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2025 (USD MILLION)
FIGURE 56. CHINA T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2025 (USD MILLION)
FIGURE 57. INDIA T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2025 (USD MILLION)
FIGURE 58. INDONESIA T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2025 (USD MILLION)
FIGURE 59. JAPAN T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2025 (USD MILLION)
FIGURE 60. MALAYSIA T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2025 (USD MILLION)
FIGURE 61. PHILIPPINES T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2025 (USD MILLION)
FIGURE 62. SINGAPORE T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2025 (USD MILLION)
FIGURE 63. SOUTH KOREA T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2025 (USD MILLION)
FIGURE 64. THAILAND T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2025 (USD MILLION)
FIGURE 65. EUROPE, MIDDLE EAST & AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2025 (USD MILLION)
FIGURE 66. FRANCE T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2025 (USD MILLION)
FIGURE 67. GERMANY T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2025 (USD MILLION)
FIGURE 68. ITALY T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2025 (USD MILLION)
FIGURE 69. NETHERLANDS T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2025 (USD MILLION)
FIGURE 70. QATAR T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2025 (USD MILLION)
FIGURE 71. RUSSIA T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2025 (USD MILLION)
FIGURE 72. SAUDI ARABIA T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2025 (USD MILLION)
FIGURE 73. SOUTH AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2025 (USD MILLION)
FIGURE 74. SPAIN T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2025 (USD MILLION)
FIGURE 75. UNITED ARAB EMIRATES T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2025 (USD MILLION)
FIGURE 76. UNITED KINGDOM T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2025 (USD MILLION)
FIGURE 77. GLOBAL T-CELL IMMUNOTHERAPY MARKET: FPNV POSITIONING MATRIX
FIGURE 78. GLOBAL T-CELL IMMUNOTHERAPY MARKET: SHARE, BY KEY PLAYER, 2020
FIGURE 79. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL T-CELL IMMUNOTHERAPY MARKET, BY TYPE

List of Tables
TABLE 1. GLOBAL T-CELL IMMUNOTHERAPY MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2025 (USD MILLION)
TABLE 4. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2025 (USD MILLION)
TABLE 5. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY CAR-T, BY REGION, 2018-2025 (USD MILLION)
TABLE 6. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY TCR, BY REGION, 2018-2025 (USD MILLION)
TABLE 7. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY TIL, BY REGION, 2018-2025 (USD MILLION)
TABLE 8. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2025 (USD MILLION)
TABLE 9. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, BY REGION, 2018-2025 (USD MILLION)
TABLE 10. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, BY REGION, 2018-2025 (USD MILLION)
TABLE 11. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2025 (USD MILLION)
TABLE 12. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY BISPECIFIC ANTIBODIES, BY REGION, 2018-2025 (USD MILLION)
TABLE 13. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2025 (USD MILLION)
TABLE 14. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2025 (USD MILLION)
TABLE 15. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2018-2025 (USD MILLION)
TABLE 16. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2025 (USD MILLION)
TABLE 17. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY B-CELL MALIGNANCIES, BY REGION, 2018-2025 (USD MILLION)
TABLE 18. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2025 (USD MILLION)
TABLE 19. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2025 (USD MILLION)
TABLE 20. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2018-2025 (USD MILLION)
TABLE 21. AMERICAS T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2025 (USD MILLION)
TABLE 22. ARGENTINA T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2025 (USD MILLION)
TABLE 23. BRAZIL T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2025 (USD MILLION)
TABLE 24. CANADA T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2025 (USD MILLION)
TABLE 25. MEXICO T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2025 (USD MILLION)
TABLE 26. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2025 (USD MILLION)
TABLE 27. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2025 (USD MILLION)
TABLE 28. AUSTRALIA T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2025 (USD MILLION)
TABLE 29. CHINA T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2025 (USD MILLION)
TABLE 30. INDIA T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2025 (USD MILLION)
TABLE 31. INDONESIA T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2025 (USD MILLION)
TABLE 32. JAPAN T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2025 (USD MILLION)
TABLE 33. MALAYSIA T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2025 (USD MILLION)
TABLE 34. PHILIPPINES T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2025 (USD MILLION)
TABLE 35. SINGAPORE T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2025 (USD MILLION)
TABLE 36. SOUTH KOREA T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2025 (USD MILLION)
TABLE 37. THAILAND T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2025 (USD MILLION)
TABLE 38. EUROPE, MIDDLE EAST & AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2025 (USD MILLION)
TABLE 39. FRANCE T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2025 (USD MILLION)
TABLE 40. GERMANY T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2025 (USD MILLION)
TABLE 41. ITALY T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2025 (USD MILLION)
TABLE 42. NETHERLANDS T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2025 (USD MILLION)
TABLE 43. QATAR T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2025 (USD MILLION)
TABLE 44. RUSSIA T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2025 (USD MILLION)
TABLE 45. SAUDI ARABIA T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2025 (USD MILLION)
TABLE 46. SOUTH AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2025 (USD MILLION)
TABLE 47. SPAIN T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2025 (USD MILLION)
TABLE 48. UNITED ARAB EMIRATES T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2025 (USD MILLION)
TABLE 49. UNITED KINGDOM T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2025 (USD MILLION)
TABLE 50. GLOBAL T-CELL IMMUNOTHERAPY MARKET: SCORES
TABLE 51. GLOBAL T-CELL IMMUNOTHERAPY MARKET: BUSINESS STRATEGY
TABLE 52. GLOBAL T-CELL IMMUNOTHERAPY MARKET: PRODUCT SATISFACTION
TABLE 53. GLOBAL T-CELL IMMUNOTHERAPY MARKET: RANKING
TABLE 54. GLOBAL T-CELL IMMUNOTHERAPY MARKET: SHARE, BY KEY PLAYER, 2020
TABLE 55. GLOBAL T-CELL IMMUNOTHERAPY MARKET: MERGER & ACQUISITION
TABLE 56. GLOBAL T-CELL IMMUNOTHERAPY MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 57. GLOBAL T-CELL IMMUNOTHERAPY MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 58. GLOBAL T-CELL IMMUNOTHERAPY MARKET: INVESTMENT & FUNDING
TABLE 59. GLOBAL T-CELL IMMUNOTHERAPY MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 60. GLOBAL T-CELL IMMUNOTHERAPY MARKET: LICENSE & PRICING
Note: Product cover images may vary from those shown
  • Adaptimmune Therapeutics PLC
  • Apac Biotech
  • Atara Biotherapeutics, Inc.
  • Autolus Limited
  • bluebird bio, Inc.
  • Bristol-Myers Squibb Company
  • CARsgen Therapeutics, Ltd
  • Cellectis SA
  • Chimera Bioengineering
  • Dendreon Pharmaceuticals LLC
  • Eureka Therapeutics, Inc.
  • Gilead Sciences, Inc.
  • Green Cross Corporation
  • Innovative Cellular Therapeutics
  • Iovance Biotherapeutics, Inc.
  • JW CreaGene Co., Ltd.
  • LAVA Therapeutics BV
  • Lyell Immunopharma
  • Neogene Therapeutics
  • NeoTX Therapeutics
  • Novartis AG
  • Oxford Vacmedix
  • Poseida Therapeutics
  • TScan Therapeutics, Inc.
  • Xenetic Biosciences
  • ZIOPHARM Oncology
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll